Login with Linked

Follow us on

Link Linkedin Youtube

Bizengri

Bizengri is an IV antibody therapy for adults with advanced non-small cell lung cancer or pancreatic cancer driven by NRG1 gene fusions, used after standard treatments fail. It blocks the fusion protein’s signaling to help shrink tumors and control disease progression

Molecule Details :

  • Molecule Name :

    Zenocutuzumab-Zbco

  • Innovator :

    MERUS N.V.

  • Approval Date :

    04-Dec-24

  • Data Exclusivity Expiry :

    04-Dec-28

  • Market Exclusivity Expiry :

    04-Dec-36

  • Dosage Form :

    Injection

  • Strength :

    375MG/18.75ML

  • Therapeutic Category :

    Immunomodulators

  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    6

  • 2026 :

    30

  • 2027 :

    100

  • 2028 :

    164

  • 2029 :

    217

  • 2030 :

    260

  • 2031 :

    306
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?